SB-243213
SB-243213 is a research chemical which acts as a selective inverse agonist for the 5HT2C receptor and has anxiolytic effects. It has better than 100x selectivity for 5-HT2C over all other receptor subtypes tested, and a longer duration of action compared to older 5-HT2C antagonist ligands.[1][2][3][4][5][6][7][8]
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H19F3N4O2 |
Molar mass | 428.415 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
References
- Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, et al. (August 2001). "SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety". Neuropharmacology. 41 (2): 186–99. doi:10.1016/S0028-3908(01)00054-5. PMID 11489455.
- Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR (December 2002). "Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study". Synapse. 46 (3): 129–39. doi:10.1002/syn.10116. PMID 12325040.
- Di Matteo V, Pierucci M, Esposito E (April 2004). "Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration". Journal of Neurochemistry. 89 (2): 418–29. doi:10.1111/j.1471-4159.2004.02337.x. PMID 15056285.
- Millan MJ, Brocco M, Gobert A, Dekeyne A (February 2005). "Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade". Psychopharmacology. 177 (4): 448–58. doi:10.1007/s00213-004-1962-z. PMID 15289999.
- Berg KA, Navailles S, Sanchez TA, Silva YM, Wood MD, Spampinato U, Clarke WP (October 2006). "Differential effects of 5-methyl-1-2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses". The Journal of Pharmacology and Experimental Therapeutics. 319 (1): 260–8. doi:10.1124/jpet.106.104448. PMID 16807362.
- Monti JM, Jantos H (December 2006). "Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat". European Journal of Pharmacology. 553 (1–3): 163–70. doi:10.1016/j.ejphar.2006.09.027. PMID 17059817.
- Leggio GM, Cathala A, Moison D, Cunningham KA, Piazza PV, Spampinato U (February 2009). "Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbens". Neuropharmacology. 56 (2): 507–13. doi:10.1016/j.neuropharm.2008.10.005. PMC 3130963. PMID 18977370.
- Kadiri N, Lagière M, Le Moine C, Millan MJ, De Deurwaerdère P, Navailles S (August 2012). "Diverse effects of 5-HT2C receptor blocking agents on c-Fos expression in the rat basal ganglia". European Journal of Pharmacology. 689 (1–3): 8–16. doi:10.1016/j.ejphar.2012.05.022. PMID 22643326.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.